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Summary Introduction TRC102 potentiates the activity of
cancer therapies that induce base excision repair (BER)
including antimetabolite and alkylating agents. TRC102
rapidly and covalently binds to apurinic/apyrimidinic (AP)
sites generated during BER, and TRC102-bound DNA
causes topoisomerase II-dependent irreversible strand
breaks and apoptosis. This study assessed the safety,
maximum-tolerated dose (MTD), pharmacokinetics and
pharmacodynamics of TRC102 alone and in combination
with pemetrexed. Purpose Patients with advanced solid
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tumors received oral TRC102 daily for 4 days. Two weeks
later, patients began standard-dose pemetrexed on day 1 in
combination with oral TRC102 on days 1 to 4. The
pemetrexed-TRC102 combination was repeated every
3 weeks until disease progression. Methods Twenty-eight
patients were treated with TRC102 at 15, 30, 60 or 100 mg/
m2/d. The MTD was exceeded at 100 mg/m2/d due to grade
3 anemia in 50 % of patients. TRC102 exposure increased in
proportion to dose with a mean t1/2 of 28 h. A pharmacody-
namic assay confirmed that TRC102 binds to pemetrexed-
induced AP sites at all doses studied. Stable disease or better
was achieved in 15 of 25 patients evaluable for response
(60 %), including one patient with recurrent metastatic
oropharyngeal carcinoma that expressed high levels of
thymidylate synthase, who achieved a partial response
and was progression free for 14 months. Conclusions
When administered with pemetrexed, the maximum tol-
erated dose of oral TRC102 is 60 mg/m2/d for 4 days.
Randomized controlled studies are planned to evaluate
the clinical benefit of adding TRC102 to pemetrexed
and other agents that induce BER.
Keywords TRC102 .Baseexcision repair .Methoxyamine .
Pemetrexed . First-in-human . Phase 1
Introduction
Base-excision repair (BER) is a fundamental cellular pro-
cess employed by malignant cells to reduce the cytotoxicity
of alkylating and antimetabolite chemotherapies. BER
repairs individual DNA bases that have been damaged di-
rectly through alkylation as well as abnormal bases incor-
porated into DNA by the action of antimetabolite agents.
Inhibition of BER has been proposed as a way to improve
the therapeutic index of these agents, although, heretofore,
no inhibitors of BER have been tested in clinical trials.
TRC102 (methoxyamine hydrochloride, TRACON Phar-
maceuticals Inc.) is a small molecule inhibitor of BER with
a unique mechanism of action that potentiates the activity of
a wide variety of antimetabolite and alkylating agents in
preclinical studies. [1–9] BER is a multiprotein pathway
initiated by base-specific DNA glycosylases that generate
common intermediates, apurinic and apyrimidinic (AP)
sites, containing reactive aldehydes [10]. TRC102 rapidly
and covalently binds the reactive aldehyde within the AP
sites, thereby interrupting the BER pathway. Furthermore,
TRC102 bound DNA is a topoisomerase II poison, such that
DNA cleavage occurs without religation. The resulting ac-
cumulation of DNA strand breaks then triggers cellular
apoptosis [8]. The induction of apoptosis by TRC102 is
relatively selective for cancer cells, as they typically over-
express topoisomerase II. In nonmalignant cells with low
topoisomerase II expression, TRC102-bound DNA is ex-
cised and replaced by the long patch DNA repair system
[11, 12]. The activity of TRC102 is independent of tumor
O6-methylguanine-DNA methyltransferase (MGMT) ex-
pression, DNA mismatch repair status, or p53 status and
TRC102 potentiates the activity of other DNA repair inhib-
itors, including PARP inhibitors [1, 8–10, 13–15].
Pemetrexed induces BER in response to uracil incorpo-
ration into DNA, which is removed by uracil glycosylase
[4]. TRC102 binds resulting AP sites and acts as a top-
oisomerase II poison, causing DNA strand breaks and apo-
ptosis as described above. In mice with human non-small
cell lung cancer xenografts, TRC102 extended median tu-
mor growth delay from 2 days with pemetrexed alone to
9 days with the combination without added toxicity [16]. In
repeat-dose toxicity studies, TRC102 caused anemia by
extravascular red cell lysis (i.e., through splenic sequestra-
tion of erythrocytes) at a dose 10-fold higher than that
required for activity. The anemia was reversible, not cumu-
lative or severe and unaffected by coadministration of peme-
trexed. (TRACON Pharmaceuticals, unpublished data).
This phase I study evaluated the maximum tolerated
dose (MTD), safety profile, pharmacokinetics, and phar-
macodynamics of TRC102 alone and in combination
with standard-dose pemetrexed in patients with advanced
cancer.
Patients and methods
Patient eligibility
Eligible patients had histologically proven advanced or
metastatic solid cancer for which curative therapy was un-
available, an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1, and adequate organ function as
demonstrated by an absolute neutrophil count ≥1,500 cells/
μL, hemoglobin ≥10 g/dL, platelets ≥100,000/μL, pro-
thrombin time or international normalized ratio ≤1.5 times
the institutional upper limit of normal (ULN), creatinine
≤1.5 times the ULN, bilirubin ≤1.5 mg/dL, and aspartate
and alanine transaminases ≤2.5 times the ULN (or ≤5 times
the ULN in patients with liver metastases). Patients were
excluded if they had a known history of central nervous
system disease, thromboembolic disease, clinically signifi-
cant malignant effusions, or had received cancer therapy
within 4 weeks prior to study entry. Patients were also
excluded if they had received prior high dose chemotherapy
associated with stem cell rescue, had a known disorder
associated with hemolysis, or were pregnant or lactating.
All patients signed an institutional review board-approved
informed consent form prior to undertaking study-related
procedures. The study was conducted in accordance with
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the International Conference on Harmonization Good Clin-
ical Practice (GCP) guidelines and all applicable local reg-
ulatory requirements and laws.
Study design and treatments
This was a multicenter open-label phase I study to evaluate
the safety, maximum-tolerated dose, pharmacokinetics and
pharmacodynamics of TRC102 dosed alone and in combi-
nation with pemetrexed (NCT00692159). TRC102 doses
studied were 15, 30, 60, and 100 mg/m2/d. The starting
dose was selected to be more than 10-fold lower than the
dose that caused reversible anemia from extravascular he-
molysis in the most sensitive preclinical species. The
TRC102 dose was escalated in serial cohorts of patients
using a standard 3+3 design. Dose-limiting toxicities were
defined as any grade 3 nonhematologic adverse event, grade
3 anemia, grade 4 thrombocytopenia, grade 4 febrile neu-
tropenia or grade 4 neutropenia lasting five or more days.
Adverse events occurring in cycles 1 and 2 were considered
in determining the maximum tolerated dose (MTD). Patients
who discontinued for reasons other than dose-limiting
toxicity prior to completion of cycle 2 were replaced to
ensure an adequate safety assessment of each cohort.
The MTD was defined as the highest dose that had an
observed incidence of dose-limiting toxicity of less than
33 % of patients per cohort. Intrapatient dose escalation
was not permitted. Patients were allowed to dose re-
duce for adverse events that resolved to grade 1 or
baseline and were allowed to interrupt TRC102 or
pemetrexed dosing following the 5 week dose-limiting
toxicity evaluation period.
TRC102 is a small organic amine that is highly water
soluble and nearly completely bioavailable after oral admin-
istration, and was supplied as a powder reconstituted in
Crystal Light® lemonade by the study center pharmacist in
single use bottles. In cycle 1, patients received daily oral
TRC102 on days 1 to 4 of a 2-weekcycle to allow for single-
agent safety and pharmacokinetic analyses. In cycle 2 and
beyond, patients received the same TRC102 regimen on
days 1 to 4 concurrently with the approved dose of intrave-
nous pemetrexed (500 mg/m2) on day 1 of 3-weekcycles.
Patients were premedicated with vitamin B12 (1,000 mcg),
folic acid (400 ug) and dexamethasone (4 mg twice daily the
day prior to and day of dosing) according to the Alimta®
package insert (Eli Lilly and Company, Indianapolis, IN).
On day 1 of cycle 3, the TRC102 dose was held to permit
assessment of the pharmacodynamics of pemetrexed when
administered in the absence of TRC102. The two drug
combination was continued every 3 weeks until disease
progression, unacceptable toxicity, or withdrawal of con-
sent. Colony stimulating factors including darbepoietin and
erythropoietin were permitted following cycle 2.
Study assessments
Safety was evaluated at regular intervals at baseline, during
treatment, and for 28 days after completing study therapy.
Vitals signs were recorded before and after every infusion
and weekly thereafter. Physical examination was performed
every 2 weeks. Hematology, serum chemistry and coagula-
tion parameters were analyzed at baseline and weekly there-
after. Adverse events were graded using National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 3.0.
Pharmacokinetic evaluation
Plasma for PK parameters were collected prior to dosing and
5, 15 and 30 min and 1, 2, 3, 4, 6, 8 and 24 h following the
first and fourth doses of TRC102 in cycle 1 and following
concurrent dosing of TRC102 with pemetrexed on cycle
2 day 1. TRC102 and pemetrexed concentrations were de-
termined using validated pharmacokinetic methods [13, 17].
Pharmacokinetic properties including the maximum plasma
concentration (Cmax), area under the plasma concentration
versus time curve to the time of the last measurable concen-
tration (AUClast), and terminal elimination half-life (t1/2),
were analyzed for TRC102 in each cohort using a non-
compartmental model in Winnonlin v. 5.2.1. A separate
population pharmacokinetic analysis was performed on
pooled TRC102 from C1D1 and C1D4 using a nonlinear
mixed-effect modeling approach to characterize both the
variability in pharmacokinetic parameters, and potential
covariates.
Population pharmacokinetic analysis
Parameters were estimated by maximum likelihood estima-
tion (MLE) with linearization using the stochastic approxi-
mation expectation maximization (SAEM) algorithm
combined with a MCMC (Markov Chain Monte Carlo)
procedure, in the Monolix software [18, 19]. A correlation
matrix of clearance (CL/F) against potential covariates was
used to identify initial covariates (Cov) for model develop-
ment. Final covariate selection was performed by a forward
stepwise procedure, based on a significant change (p<0.05)
in the log-likelihood. Other factors, such as parameter pre-
cision, general interpretability, and clinical relevance were
also considered in selecting covariates. The Wald test and
the Bayesian information criterion (BIC) were used to test
different covariate hypotheses regarding the final model. For
the goodness-of-fit, observed and predicted concentrations
versus time, observed concentrations vs. population predic-
tions, weighted residuals vs time and weighted residuals vs.
predictions were evaluated. A proportional error model was
used to describe the residual variability, and inter-individual
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variability (IIV) was modeled with covariates as exponential
terms according to Individual Parameter (Pi)0Typical Value
Population Parameter θð Þ  Covð Þb  eη;Pi, where β was the
change in Ln(Pi) per unit change in Ln(Cov), and the IIV is
reported as the standard deviation (ω) of η error.
Pharmacodynamic analysis
Peripheral blood mononuclear cells were collected before
treatment with pemetrexed alone on cycle 3 day 1 and then
at four and 24 h following treatment, and at the same time
points before and after treatment with pemetrexed and
TRC102 on cycle 2 day 1. The number of AP sites in
peripheral blood mononuclear cells was measured using
an aldehyde reactive probe from Dojindo Molecular
Technologies, Inc. (Gaithersburg, MD) as previously
described and normalized to the pre-dose value determined
for each patient [8].
Thymidylate synthase immunohistochemistry
Archival tumor samples from selected patients were sent to
Caris Life Sciences (Irving, TX) for thymidylate synthase
(TS) immunohistochemistry. Formalin-fixed, paraffin em-
bedded tumors were cut into 4 μm sections and mounted
on poly-L-lysine-coated slides, processed for epitope re-
trieval, and stained with a mouse anti-thymidylate synthase
cocktail from Invitrogen Corporation (Carlsbad, CA) and
appropriate controls as previously described [20]. Staining
intensity was calculated as 0 (none), +1 (weak), +2
(distinct), or +3 (very strong). A value designated as the
HSCORE was obtained for each tumor by multiplying the
staining intensity times the percentage of cells that stain at
that intensity. An HSCORE ≥30 was considered TS-positive
based on survival correlations reported previously [21].
Evaluation of tumor response
Tumor response and progression were assessed using the
original Response Evaluation Criteria in Solid Tumors
(RECIST) [22]. Evaluations were performed at baseline, at
the end of cycle 3 and then every two to three cycles or
earlier if disease progression was suspected.
Statistical analysis
The safety population included all patients who received
at least one dose of TRC102. Descriptive statistics (such
as means, medians, standard deviations and ranges for
continuous data and percentages for categorical data)
were used to summarize patient characteristics, treatment
administration, safety, efficacy, pharmacokinetic, and
pharmacodynamic parameters.
Results
Patient characteristics and disposition
Between June 2008 and December 2009, 28 patients
with advanced or metastatic solid tumors were enrolled
and treated with escalating doses of TRC102 at 15, 30,
60 or 100 mg/m2 daily for days 1 through 4 of a
2 weekcycle and then days 1 through 4 of a 3 week
cycle in combination with 500 mg/m2 of pemetrexed on
day 1. Baseline patient characteristics are summarized in
Table 1. All patients enrolled received at least one dose
of TRC102, and 25 of 28 completed the 5-week evalu-
ation period for dose-limiting toxicity (DLT). Reasons
for early withdrawal were unrelated adverse events in
two patients (ischemic stroke and COPD exacerbation)
and rapidly progressive disease in a patient with meta-
static ovarian cancer. Twenty-six of 28 patients enrolled
received at least two cycles of TRC102 (8 doses), 20
received at least three cycles (11 doses), 12 received at
least four cycles (15 doses), and one patient at 30 mg/
m2/d received 21 cycles (83 doses) of TRC102 therapy.
Table 1 Patient characteristics
Characteristic Number of patients %
Total number of patients treated 28
Sex
Male 12 43
Female 16 57
Age, years
Median 60
Range 19 86
ECOG PS
0 9 32
1 19 68
Tumor type
Epithelial ovarian cancer 4 14
Non squamous NSCLC 3 11
Squamous NSCLC 3 11
Pancreatic cancer 3 11
Colorectal cancer 3 11
Sarcoma 3 11
Othera 9 32
No. of prior chemotherapy regimens
Median 3
Range 1 11
ECOG Eastern Cooperative Oncology Group; PS performance status;
NSCLC non small cell lung cancer
a Other tumor types were adenoid cystic, bladder, breast, cholangiocar
cinoma, esophageal, head and neck, prostate, peritoneal and uterine
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Safety and tolerability
Dose escalation proceeded stepwise until the top dose of
100 mg/m2/d was reached. Four patients were enrolled in
the 15 mg/m2/d cohort, as one patient developed a COPD
exacerbation and received only three doses of TRC102,
making him unevaluable for DLT. Expansion of the
30 mg/m2/d cohort was required per protocol due to the
occurrence of grade 3 anemia during cycle 2 in a patient
with metastatic prostate cancer whose hemoglobin de-
creased from 10.4 g/dL prior to dosing to 7.9 g/dL at cycle
2 day 8. This 81 year old man with castrate resistant and
chemotherapy refractory prostate cancer and metastases to
bone, liver and lymph nodes continued on a reduced dose of
TRC102 of 15 mg/m2/d for five cycles prior to disease
progression. One additional patient at this dose level was
unevaulable due to the occurrence of an unrelated ischemic
stroke prior to completion of the DLT evaluation period.
The MTD of TRC102 was exceeded at 100 mg/m2/d due
to DLT of grade 3 anemia in three of six patients (Table 2).
All patients at this dose level developed grade 2 or 3 anemia,
five of six patients required transfusion, and the one patient
who was not transfused was treated with darbepoietin. Ane-
mia was generally manifest by cycle 2 in these patients and
four patients required dose reductions. One 47 year old
woman with chemotherapy-refractory metastatic ovarian
cancer dosed at 100 mg/m2/d developed grade 3 anemia
during treatment with TRC102 alone in cycle 1 (hemoglobin
decrease from 10.9 g/dL at screening 5 days prior to treat-
ment, to 9.4 g/dL immediately prior to the initial TRC102
dose, to 7.6 g/dL 1 week following dosing). The patient
remained on study for 7 cycles following transfusion
and dose reduction to 50 mg/m2/d prior to developing
progressive disease.
Following determination of the MTD at 60 mg/m2/d,
eight additional patients were enrolled at this dose level to
further assess safety. One 74 year old woman with
chemotherapy-refractory metastatic uterine carcinoma de-
veloped grade 3 anemia in cycle 1 following dosing with
TRC102 alone. This patient with chemotherapy-associated
anemia was granted an exception to enter the study with a
hemoglobin level slightly lower than 10.0 g/dL and devel-
oped a decrease in hemoglobin from 9.7 g/dL prior to
dosing to 7.9 g/dL over 1 week, prompting transfusion.
The patient remained anemic throughout treatment, devel-
oping grade 4 anemia in cycle 4 that required further trans-
fusion and she elected to discontinue treatment.
Anemia was the only DLT reported and was not accom-
panied by significant thrombocytopenia or leukopenia.
Anemia was characterized by an elevated reticulocyte pro-
duction index and laboratory signs of extravascular hemo-
lysis (decreased plasma haptoglobin and increased total
bilirubin without hemoglobinuria) that were more frequent
as the dose of TRC102 was escalated (Table 2). Additional
laboratory and clinical evaluations excluded common
causes of anemia including blood loss, plasma volume
expansion, iron deficiency, and vitamin B-12 or folate
deficiency. The severity of anemia generally did not
increase as the number of treatment cycles accumulated
and the anemia was reversible and manageable with
standard supportive measures including growth factors
and packed red cell transfusion. The frequency of red
blood cell transfusions and growth factor support in-
creased with TRC102 dose, as did the need for dose
reduction (Table 2).
Anemia was the only grade 3 or higher treatment-related
adverse event noted following dosing with TRC102 alone in
cycle 1, and treatment with TRC102 and pemetrexed in
cycle 2 and beyond resulted in infrequent episodes of mye-
losuppression similar to that reported for pemetrexed alone
(Table 3). Treatment-related nonhematologic adverse events
were generally mild to moderate (Table 3). The only excep-
tions were one patient with grade 3 fatigue and another with
grade 3 diarrhea who received 100 mg/m2/d of TRC102
with pemetrexed.
Pharmacokinetics
TRC102 pharmacokinetic properties are presented in Table 4.
The overall mean half life (t1/2) of 28 h was unchanged with
increasing doses (p00.875) or cycle, and the exposure
increased proportionally with dose (Fig. 1, AUC/Dose,
Table 2 Frequency of grade 3/4 anemia, associated chemistry values and treatment over the full duration of the study by cohort (N028)
TRC102 Dose
in mg/m2/d (n)
Grade 3
anemia
Grade 4
anemia
Haptoglobin
decrease
Bilirubin
increase
Red cell
transfusion
Erythropoietin
or darbepoietin
TRC102
dose reduction
15 (4) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 1 (25 %) 0 (0 %) 0 (0 %)
30 (7) 1 (14 %) 0 (0 %) 0 (0 %) 1 (14 %) 3 (43 %) 1 (14 %) 1 (14 %)
60 (11) 3 (27 %) 1 (9 %) 1 (9 %) 4 (36 %) 6 (54 %) 3 (27 %) 1 (9 %)
100 (6) 3 (50 %) 0 (0 %) 3 (50 %) 4 (67 %) 5 (83 %) 2 (33 %) 4 (67 %)
n number of patients evaluable for safety.
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ANOVA p00.98). The target AUC was exceeded in all
patients who received at least four doses of TRC102. Pharma-
cokinetic parameters were similar when TRC102 was admin-
istered without pemetrexed on cycle 1 day 1 or with
pemetrexed on cycle 2 day 1. TRC102 accumulated with daily
dosing; the target Cmax of 50 ng/mL for in vivo activity was
achieved by the fourth daily dose in two of three patients
treated at 15 mg/m2/d and all patients receiving 30 mg/m2/d
and higher doses. In addition, pemetrexed exposure analyzed
following dosing in cycle 2 day 1 (with coadministration of
TRC102) was similar to published exposures (Alimta®
package insert (Eli Lilly and Company, Indianapolis,
IN); data not shown).
The population pharmacokinetics of TRC102 were
evaluable in 19 patients who received doses on C1D1 thru
C1D4. The structural PK model was satisfied as one com-
partment with first-order absorption (Ka) and without lag-
time. The fixed and random effects determined in the final
model are listed in Table 5. Interindividual variability was
estimated for the elimination rate constant (Kel) and the
apparent volume of distribution (V/F). Significant covari-
ates were identified to be related to the variability in V/F,
namely, sex (M, F), baseline alanine transaminase (ALT),
baseline serum creatinine (SrCr) and baseline serum albu-
min (Albu), whereas Kel was identified as significantly
related to sex. The influence of SrCr on volume of distribu-
tion (and hence the Clearance) was greater than the other
covariates. Table 6 summarizes the covariate model building
steps for the significant covariates, which was effective at
explaining variability in PK parameters for male patients,
but not female patients in this study, as the inter-individual
variability in Kel and V/F was reduced in males from by 25
and 56 %, respectively.
Pharmacodynamics
The binding of TRC102 to pemetrexed-induced AP sites
was evaluated in peripheral blood mononuclear cells
(PBMC) of a subset of patients. Comparison was made
between AP site availability in PBMC on cycle 2 day 1
(when TRC102 and pemetrexed were administered concur-
rently) and cycle 3 day 1 (when TRC102 was held and
pemetrexed was administered alone). As summarized in
Table 7 and presented in Fig. 2, administration of peme-
trexed in the absence of TRC102 on cycle 3 day 1 generally
caused an increase in the number of AP sites (detected
Table 3 Frequency of adverse events over the full duration of the
study related to TRC102, excluding anemia (N028)
Preferred terma Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 1 3
Fatigue 6 3 1b
Diarrhea 1 1b
Leukopenia 1
Nausea 3 3
Vomiting 3
Anorexia 6
Mucosal inflammation 3
Pruritus 3
Pyrexia 3
Rash 2
a Includes events occurring in more than 1 patient, and all grade 3 and
higher events
b Patient was enrolled and treated at 100 mg/m2 /d TRC102
Table 4 TRC102 pharmacoki
netic properties by cohort
All values expressed as medians
with ranges in parentheses.
Cmax maximum concentration;
t1/2 half life; AUC0 ∞ area under
the serum concentration time
curve for zero to infinity.
No. Cmax (ng/mL) t1/2 (hr) AUC0 ∞ (hr ng/mL)
Cycle 1 Day 1
15 mg/m2/d 3 19.7 (12.7 57.4) 37.3 (34.1 41.2) 287 (219 1132)
30 mg/m2/d 6 64.3 (22.7 205.0) 21.8 (15.9 25.5) 1041 (263 3462)
60 mg/m2/d 3 119.0 (63.7 126.0) 21.9 (17.6 29.9) 1991 (1093 2161)
100 mg/m2/d 5 152.0 (83.5 417) 26.8 (14.1 44.0) 2312 (987 5331)
Cycle 1 Day 4
15 mg/m2/d 3 68.1 (27.0 129) 41.5 (36.0 52.2) 1136 (188 2580)
30 mg/m2/d 6 126.0 (73.2 282.0) 30.9 (26.5 59.4) 1960 (1158 5230)
60 mg/m2/d 3 327.0 (155.0 626.0) 26.9 (25.8 44.8) 5812 (2632 11075)
100 mg/m2/d 5 247.0 (148.0 435.0) 25.0 (16.4 36.6) 3105 (2066 7969)
Cycle 2 Day 1
15 mg/m2/d 3 24.6 (18.2 56.0) 34.3 (5.6 55.4) 297 (126 1186)
30 mg/m2/d 6 57.4 (25.6 137.0) 21.9 (12.6 43.3) 943 (381 2071)
60 mg/m2/d 3 103.0 (93.6 239.0) 26.7 (25.4 28.0) 1654 (1332 4556)
100 mg/m2/d 5 225.0 (74.9 385.0) 37.0 (25.3 45.5) 3697 (940 6176)
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through binding of a reactive aldehyde group) relative to
baseline, indicating that pemetrexed induced the BER path-
way. These sites were masked during concurrent adminis-
tration of pemetrexed and TRC102 on cycle 2 day 1,
indicating TRC102 bound AP sites could no longer were
detectable by the aldehyde reactive probe. Increased AP
sites in PBMC relative to baseline were noted in 10 of 11
patient samples assayed following treatment with peme-
trexed alone, and the increase was reduced in PBMC col-
lected following treatment with both agents.
Clinical activity
All 28 patients had RECIST-defined measurable disease, and
25 underwent at least one response assessment. Fifteen
patients (60 %) had a best response of stable disease or better
lasting ≥3 cycles, including a 61 year old woman with meta-
static oropharyngeal adenoid cystic cancer treated previously
with cetuximab, docetaxel and carboplatin, who had a partial
response (with maximal reduction in the diameter of the
mediastinal lymph node metastasis of 33 %) and remained
progression free for 21 cycles (14 months). In addition, 14
patients had stable disease for ≥3 cycles including patients
with squamous cell lung cancer (n03), epithelial ovarian
cancer (n03), colorectal cancer (n02), nonsquamous non-
small cell lung cancer (n01), pancreatic cancer (n01), pros-
tate cancer (n01), endometrial cancer (n01), head and neck
cancer (n01) and breast cancer (n01). Patients with pro-
longed stable disease were noted across all four dose cohorts
without clear dose dependency.
Thymidylate synthase immunohistochemistry
Archival formalin-fixed paraffin-embedded tumor tissue was
assessed for thymidylate synthase immunohistochemistry in
three patients who developed stable disease beyond 3 cycles
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Fig. 1 Relationship between dose of TRC102 and median AUC∞ for
nineteen patients treated on C1D1. The exposure of TRC102 was
proportional to dose across the range of 15 to 100 mg/m2/d
Table 5 TRC102 population
pharmacokinetic parameters on
C1D1 and C1D4
SrCr serum creatinine, ALT ala
nine transaminase, Albu albumin
Population parameters Base model estimate ± s.e Covariate model estimate ± s.e.
Fixed effects θ
Elimination Kel (hr 1) 0.0359 0.0036 0.0399 0.0042
Volume of Distribution V/F (L/m2) 5.73 1.1 3.55 2.6
Absorption Ka (hr 1) 4.17 0.39 3.93 0.36
Random effects η
IIV ωKel (sex0F, n011) 0.288 0.09 0.278 0.093
IIV ωKel (sex0M, n08) 0.685 0.19 0.431 0.013
IIV ωV (sex0F, n011) 0.781 0.16 0.69 0.15
IIV ωV (sex0M, n08) 0.716 0.18 0.161 0.084
IIV Correlation (Kel,V/F) 0.614 0.17 0.385 0.27
Residual error
σ 0.378 0.014 0.38 0.014
Covariates
βV(SexM) 0.866 0.24
βV (ALT) 0.0177 0.0033
βV (SrCr) 1.01 0.45
βV (Albu) 0.39 0.14
βKel(SexM) 0.445 0.033
Parameters by group
Kel (sex0F, n011) 0.0399 0.0042
Kel (sex0M, n08) 0.0256 0.0046
V/F (sex0F, n011) 3.55 1.6
V/F (sex0M, n08) 1.49 0.74
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with tumor types that may express high levels of TS. The
patient with metastatic oropharyngeal adenoid cystic carcino-
ma who achieved a partial response had 1+ staining intensity
in 30 % of tumor cells giving her a positive HSCORE indi-
cating high thymidylate synthase expression and low likeli-
hood of response to pemetrexed [21]. Two patients with
squamous cell lung cancer, who remained on study for
9 cycles, had 2+ intensity in 1–2 % of tumor cells giving them
negative HSCORES of <5 %.
Discussion
This study is the first to assess the pharmacological effects
of TRC102 in humans, establishing a maximum tolerated
daily oral dose in combination with the approved dose of
pemetrexed chemotherapy. The MTD was 60 mg/m2/d for
4 days in combination with standard-dose pemetrexed every
3 weeks. At 100 mg/m2/d, the MTD was exceeded due to
extravascular hemolytic anemia requiring transfusion and
dose-reduction and was consistent with preclinical testing.
The anemia of TRC102 is remarkably predictable, occur-
ring over a similar time course in rats, dogs, and cancer
patients, typically within the first 3 weeks of treatment and
not increasing in severity of anemia as the number of treat-
ment cycles accumulated. In mice, TRC102 caused anemia
at a dose 10-fold higher than those required for efficacy.
Because of the large therapeutic window, TRC102 could be
administered at a initial dose of 15 mg/m2/d that was pro-
jected to be efficacious. The wide safety margin is supported
by pharmacodynamic data from the current study showing
TRC102 bound to AP sites and achieving desired pharma-
cokinetic exposures at all doses studied with extravascular
hemolysis limited to the higher doses.
The mechanism of TRC102-induced extravascular hemo-
lysis is clearly different from the mechanism for activity
since erythrocytes lack DNA and AP sites for TRC102 to
bind. Hemolysis is believed to result from TRC102 binding
to reactive aldehydes that accumulate on the plasma mem-
brane of aging erythrocytes, thereby targeting them for early
removal from the circulation by reticuloendothelial macro-
phages, primarily in the spleen [23].
Importantly, the current trial confirmed preclinical findings
indicating that TRC102 does not potentiate chemotherapy-
induced myelosuppression. In addition, grade 3 or higher
drug-related nonhematologic toxicity was rare and observed
only above the MTD of 60 mg/m2/d.
TRC102 pharmacokinetic parameters were dose-
proportional with an overall mean t1/2>28 h. By the fourth
daily TRC102 dose, all patients achieved the target plasma
AUC and all but one patient achieved the desired Cmax of
50 ng/mL, that was associated with preclinical activity. Impor-
tantly, drug interactions between TRC102 and pemetrexed
were not observed, which was consistent with preclinical
testing. The variability in pharmacokinetics between patients
were significantly influenced by both gender and baseline
serum creatinine (see online Figure S6 and S7). The alanine
transaminase and serum albumin were also significant cova-
riates, however the beta coefficients were comparatively small
Table 7 Percentage increase (or decrease) of apurinic sites in periph
eral blood mononuclear cells in the absence of TRC102 on cycle 3 day
1 compared to in the presence of TRC102 on cycle 2 day 1, at 4 and
24 hours following dosing of pemetrexed
TRC102 Dose Group015 mg/m2
Patient 4 hr 24 hr
10063002 29 % 16 %
10033001 26 % 0 %
10033003 50 % 51 %
Mean 2 % 12 %
TRC102 Dose Group030 mg/m2
Patient 4 hr 24 hr
10063003 55 % 11 %
10013003 18 % 42 %
10013005 58 % 2 %
Mean 44 % 18 %
TRC102 Dose Group060 mg/m2
Patient 4 hr 24 hr
10033004 50 % 62 %
10013006 191 % 122 %
Mean 121 % 92 %
TRC102 Dose Group0100 mg/m2
Patient 4 hr 24 hr
10063005 6 % 134 %
10033005 133 % 93 %
10013007 22 % 8 %
Mean 54 % 78 %
Fig. 2 Representative pharmacodynamic data from a patient treated with
pemetrexed plus 60 mg/m2/d TRC102. AP sites in peripheral blood
mononuclear cells were detected using a fluorescent aldehyde reactive
probe, and results were expressed relative to pre dose. The number of AP
sites increased after dosing with pemetrexed alone (cycle 3 day 1) but not
after dosing with pemetrexed and TRC102 (cycle 2 day 1). These findings
are consistent with binding of TRC102 to pemetrexed induced AP sites
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and so were not considered heavily influential on the PK.
Overall, we observed the PK parameters (Kel and V/F) were
significantly larger in female patients, and therefore Clearance
(CL0Kel*V/F) was much slower in male patients. The model
provides an indication that these covariates were important for
explaining PK variability among males in this cohort of
patients, and are generally not considered predictive in other
or larger cohorts.
Durable stable disease was achieved in a variety tumor
types including patients with squamous and nonsquamous
non-small cell lung cancer. A partial response lasting 21 cycles
(14 months) was seen in a patient with metastatic oropharyn-
geal cancer that expressed high levels of thymidylate syn-
thase. These findings suggest that TRC102 plus pemetrexed
should be further evaluated in patients with cancers that are
typically resistant to pemetrexed alone [24, 25].
In summary, TRC102 is a novel targeted therapy that is
well-tolerated at clinically relevant doses in combination
with pemetrexed chemotherapy, achieved desired PK and
PD endpoints and was associated with activity when dosed
with pemetrexed in patients unlikely to respond to peme-
trexed treatment alone. The results of the current trial sup-
port rationally designed phase II studies to determine the
clinical benefit of TRC102 in combination with pemetrexed
in patients with non-small cell lung cancer and other cancer
types. TRC102 is also undergoing clinical testing combina-
tion with temozolomide (NCT00892385) and preclinical
data support additional combination studies with wide vari-
ety of cancer therapies including antimetabolites, oxidizing
agents, alkylating agents, and PARP inhibitors [1–9].
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